Previous 10 | Next 10 |
Today, we circle back on Gamida Cell Ltd., a small developmental company based in Israel for the first time since last November. The company has a key FDA approval pending which could shift the trajectory of the company and the stock. An investment analysis follows in the paragrap...
Image source: The Motley Fool. Gamida Cell Ltd. (NASDAQ: GMDA) Q2 2022 Earnings Call Aug 15, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript
Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Conference Call August 15, 2022, 08:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Julian Adams - CEO Ronit Simantov - CMO & Chief Scientific Officer Michele Korfin ...
Gamida Cell press release ( NASDAQ: GMDA ): Q2 GAAP EPS of -$0.31 misses by $0.02 . As of June 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $55.1M. Gamida Cell expects that its current cash, cash equivalents and investments will support...
- Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 - - Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell...
Gamida Cell ( NASDAQ: GMDA ) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.29 (+61.8% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and 2 downward. Fo...
-The company-sponsored Phase 1/2 study is evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy ...
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 202...
AMTD IDEA ( AMTD ) +323% . 36Kr Holdings ( KRKR ) +70% . Quoin Pharmaceuticals ( QNRX ) +54% . Intelligent Living ( ILAG ) +40% . Getty Images Holdings ( GETY ) +24% stock rallies for second day, shares gain 19%. Innoviz ...
The U.S. Food and Drug Administration (FDA) granted priority review to Gamida Cell's ( NASDAQ: GMDA ) application seeking approval of stem cell therapy omidubicel to treat patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. The ...
News, Short Squeeze, Breakout and More Instantly...
Gamida Cell Ltd. Company Name:
GMDA Stock Symbol:
NASDAQ Market:
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
2024-04-03 06:21:00 ET How to Analyze Different Penny Stocks Sectors to Make Money Investing in penny stocks offers an accessible entry point for individuals aiming to participate in the stock market with a lower initial investment. Analyzing different sectors within the realm of penn...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...